Norwich Expands Capabilities for Phase I-III Clinical Trials

Norwich Expands Capabilities for Phase I-III Clinical Trials
Growing market demand leads to expansion at two research facilities

Norwich, New York - February 2, 2012 - Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I - III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.

"Utilizing proven technologies and this new, modern clinical facility, NCS is now able to offer functional expertise and therapeutic experience with reliability that will create cost and time efficiency for customers," stated Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services. "We are proud to be opening this new clinical trial facility with full regulatory approval from the Drugs Controller General of India as an indication of our unequivocal adherence to GCP, GLP, CFR part 11 and other applicable regulatory requirements."

The 72-bed, 16,500 square foot facility has been successfully audited by the Drugs Controller General of India and contains separate areas for subject screening and blood draws, an onsite pharmacy and a fully equipped intensive care unit. In conjunction with this new facility opening, Norwich Clinical Services is also conducting additional clinical programs within a
separate FDA and EMA-approved research facility. Studies conducted at this 86-bed facility have been submitted to prominent health agencies including FDA, EMA, TPD, MHRA and DCGI.

"Our customers' needs are rapidly evolving for contract pharmaceutical services and we understand that Norwich capabilities must also evolve to include one comprehensive solution for all stages of the product lifecycle," said Terry Novak, president of Norwich Pharmaceuticals, the parent company for Norwich Clinical Services. "Combining the clinical trial capabilities of these two research facilities will meet a specific need for Norwich customers seeking budget efficiency and schedule adherence from the early stages of development through study-end reconciliation."

About Norwich Clinical Services
Norwich Clinical Services is a global clinical research organization that conducts Phase I-III clinical trials, Phase IV post market surveillance, BA/BE studies, pharmacovigilance, laboratory and bioanalytical services for the pharmaceutical and biotech industries. With operations in Asia, Europe and North America, NCS offers study management, project coordination for clinical trial recruitment, and investigator collaboration led by physician teams with targeted therapeutic experience, having completed more than 50 clinical trial programs and 2,000 biostudies.

Norwich Clinical Services combines clinical expertise, exceptional customer focus, and the highly-respected resources and reputation of Norwich to offer a complete range of clinical services. Visit www.norwichpharma.com/clinical for detailed information.

About Norwich Pharmaceuticals
Norwich has been serving the pharmaceutical industry for 125 years and is a recognized
leader in full service contract pharmaceutical development and manufacturing. As a singlesource
provider, Norwich customers receive greater flexibility, resources and speed that result
in a streamlined progression from product development to scale-up and commercial
manufacturing through clinical services.

####
Media and Business Inquiries:
Joseph Miller
Director, Marketing
Norwich Pharmaceuticals
Tel: 862.485.0023
E-mail: [email protected]

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.